chufangao/CTO huggingface dataset:
Clinical trial NCT02913482: Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy
Official title: A Two Part Seamless, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Infants With Type 1 Spinal Muscular Atrophy
Acronym: FIREFISH
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 62.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-12-23
Primary completion date: 2019-11-14
Completion date: 2023-12-22
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT03394937: Safety of Intranodal ECI-006 in Melanoma Patients
Official title: Study to Assess the Safety and Tolerability of ECI-006 mRNA Immunotherapy by Intranodal Administration in Melanoma: (1) Following Surgical Resection, and (2) in Patients With Stable Disease After Standard of Care Immunotherapy Treatment
Sponsor: eTheRNA immunotherapies (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Expiry of study medication
Enrollment: 21.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-06-27
Primary completion date: 2020-12-31
Completion date: 2021-01-29
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04115384: Intranasal Insulin in Frontotemporal Dementia (FTD)
Official title: A Single Center Feasibility Study of Intranasal Insulin in Frontotemporal Dementia NIFT-D
Sponsor: HealthPartners Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: COVID - unable to restart after restrictions were lifted
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-09-09
Primary completion date: 2020-02-26
Completion date: 2023-05-15
Clinical trial NCT03965494: AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery
Official title: Pilot Surgical PK Study of BGB324 in Recurrent Glioblastoma Patients
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: NCI decided to terminate ABTC Consortium due to NCI moving in different direction for Brain Cancer - official close date is 10/31/23
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-02
Primary completion date: 2023-10-31
Completion date: 2023-10-31
Plan to share individual participant data: NO
Clinical trial NCT04393727: Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19
Official title: Transfusion of Convalescent Plasma for the Early Treatment of pneumonIa Due to SARSCoV2: a Multicenter Open Label Randomized Control Trial
Acronym: TSUNAMI
Sponsor: Azienda Ospedaliero, Universitaria Pisana (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study was stopped because the Promoter was changed and a new study on convalescent plasma promoted by AIFA was started in Italy.
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-01
Primary completion date: 2020-09-30
Completion date: 2020-09-30
Plan to share individual participant data: NO
Clinical trial NCT02435849: Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
Official title: A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
Acronym: ELIANA
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 80.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-04-08
Primary completion date: 2020-01-21
Completion date: 2022-11-17
Baseline population: Full Analysis Set (FAS): The Full analysis set comprised all patients who received infusion of tisagenlecleucel.
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03312738: A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor
Official title: A Randomized, Double-blind, Placebo Controlled, Phase II Study of Everolimus in Combination With Exemestane in the Treatment of Chinese Postmenopausal Women With Estrogen Receptor Positive, HER-2 Negative, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Prior Letrozole or Anastrozole
Acronym: BOLERO-5
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 159.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-15
Primary completion date: 2022-04-25
Completion date: 2022-04-25
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03504917: A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
Official title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: A futility analysis assessed that the study is highly unlikely to meet the pre-defined primary objective of the study. No new safety concerns were identified.
Enrollment: 322.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-08-08
Primary completion date: 2020-03-04
Completion date: 2020-07-01
Clinical trial NCT04474483: Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19
Official title: A Pilot Placebo-controlled Randomized Double-blind Trial of Melatonin in Outpatients With COVID-19 Infection
Acronym: COVID-19
Sponsor: State University of New York at Buffalo (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: difficult recruitment and complete first visit in person during thne hight of tne pandemic and later not enough subjects
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-06
Primary completion date: 2022-07-22
Completion date: 2022-07-22
Clinical trial NCT02620280: Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1
Official title: Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment With Nab-paclitaxel and Carboplatin
Acronym: NeoTRIPaPDL1
Sponsor: Fondazione Michelangelo (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 278.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-04-30
Primary completion date: 2024-01-31
Completion date: 2024-01-07
Clinical trial NCT04958967: Phase Ib Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation
Official title: A Phase Ib Open-Label, Randomization Multi-Center Study to Evaluate Efficacy And Safety of FURMONERTINIB MESILATE IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER HARBOURING EGFR EXON 20 INSERTION MUTATION
Sponsor: Allist Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: The protocol need to review
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-01
Primary completion date: 2022-05-01
Completion date: 2022-08-01
Plan to share individual participant data: NO
Clinical trial NCT03126760: Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)
Official title: A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of Acthar® in Subjects With Relapsing-remitting Multiple Sclerosis
Acronym: OPTIONS
Sponsor: Mallinckrodt (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Recruitment difficulties and COVID-19 logistical challenges; no safety concerns
Enrollment: 35.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-05-22
Primary completion date: 2020-07-14
Completion date: 2020-07-14
Baseline population: All participants
Limitations and caveats: The study was terminated early by sponsor decision because of recruitment difficulties and the impact of the COVID-19 pandemic. The planned analyses did not change except that the total sample size was reduced. Inferential statistics were not performed. Results are nominal because the sample size did not reach that specified in the protocol.
Plan to share individual participant data: NO
IPD sharing description: Discussion of statistical endpoints and analysis are included in manuscripts. Summary aggregate (basic) results (including adverse events information) and the study protocol are made available on clinicaltrials.gov (NCT03126760) when required by regulation. Individual de-identified patient data will not be disclosed. Requests for additional information should be directed to the company at medinfo@mnk.com.
Clinical trial NCT02814175: A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)
Official title: A Phase 4 Open-label Randomized Controlled Study COmparing the Effectiveness of Adalimumab iNTROduction and Methotrexate Dose escaLation in Subjects With Psoriatic Arthritis (CONTROL)
Acronym: CONTROL
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 246.0 (ACTUAL)
Number of arms: 6.0
Start date: 2016-08-05
Primary completion date: 2019-09-23
Completion date: 2020-03-19
Baseline population: The Intent-To-Treat Part 1 (ITT Part 1) population comprises all participants who were randomized and received at least one dose of the study medication during Part 1.
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Clinical trial NCT04513548: Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria
Official title: A Two-part Exploratory Study Combining a Pilot Study in Healthy Subjects and Chronic Spontaneous Urticaria Patients (Part 1) and a Randomized, Subject, Investigator and Sponsor-blinded, Placebo Controlled, Study (Part 2) to Assess the MechAniSm of acTion of ligElizumab (QGE031) in Patients With Chronic uRticaria (MASTER)
Acronym: MASTER
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Company decision
Enrollment: 11.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-05
Primary completion date: 2022-07-19
Completion date: 2022-07-19
Plan to share individual participant data: NO
IPD sharing description: Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT04540120: Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome
Official title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Orally Administered Dapansutrile Capsules for the Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome
Sponsor: Olatec Therapeutics LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Terminated due to the treatment environment for COVID-19 evolving with the pervasiveness of vaccinations and other therapeutic modalities in mitigating against severe infection that has eliminated a viable patient population for study enrollment.
Enrollment: 49.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-24
Primary completion date: 2022-07-28
Completion date: 2022-07-28
Clinical trial NCT02997956: Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)
Official title: Phase IB/II Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)
Sponsor: University of Michigan Rogel Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: funding issues
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-07-31
Primary completion date: 2020-07-31
Completion date: 2022-07-31
Clinical trial NCT05545072: Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)
Official title: A Randomized, 52-week Treatment Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray
Acronym: ADAPT
Sponsor: Emory University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The study was terminated due to funding ending.
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-10-26
Primary completion date: 2024-07-10
Completion date: 2024-07-10
Plan to share individual participant data: YES
IPD sharing description: The investigators plan to share individual participant data that underlie the results reported in the article, after deidentification (text, tables, figures, and appendices)
IPD time frame: The investigators will share de-identified data beginning 3 months and ending 5 years following article publication.
IPD access criteria: Proposals should be directed to joshua.levy2@emory.edu. To gain access, data requestors will need to sign a data access agreement. Data are available for 5 years at a third-party website.
Clinical trial NCT03768219: Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis
Official title: Phase 1 Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis
Sponsor: Aptevo Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business decision
Enrollment: 85.0 (ACTUAL)
Number of arms: 14.0
Start date: 2019-03-18
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Plan to share individual participant data: NO
Clinical trial NCT04112303: Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis
Official title: A Phase 3 Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic HCV Infection and Compensated Cirrhosis
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 37.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-10-16
Primary completion date: 2021-03-26
Completion date: 2021-06-25
Baseline population: Safety Analysis Set included all participants who took at least 1 dose of the study drug.
Plan to share individual participant data: YES
IPD sharing description: Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy
IPD time frame: 18 months after study completion
IPD access criteria: A secured external environment with username, password, and RSA code.
Clinical trial NCT01742273: Vitamin K1 to Slow Progression of Vascular Calcification in HD Patients
Official title: Vitamin K1 to Slow Progression of Vascular Calcification in Hemodialysis Patients
Acronym: VitaVasK
Sponsor: RWTH Aachen University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Termination stopped due to low recruitment rates
Enrollment: 63.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-10-31
Primary completion date: 2020-07-17
Completion date: 2020-07-17
Clinical trial NCT03298022: Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UC
Official title: Efficacy and Safety of ALTB-168 in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis: a 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial
Acronym: TNF
Sponsor: AltruBio Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: As a consequence of operational difficulties at the clinical sites associated with the COVID-19 pandemic
Enrollment: 24.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-05-04
Primary completion date: 2020-04-06
Completion date: 2020-06-01
Baseline population: Safety population /The mITT set was defined as all patients who were enrolled and who received at least one dose of ALTB-168 treatment.
Plan to share individual participant data: NO
Clinical trial NCT05201937: A Study of JNJ-64281802 in Healthy Adult Participants
Official title: A Phase 1, Open-Label Study in Healthy Adult Participants to Assess the Pharmacokinetics of JNJ-64281802 Administered as Different Multiple Dose Regimens
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 33.0 (ACTUAL)
Number of arms: 6.0
Start date: 2022-02-23
Primary completion date: 2022-12-11
Completion date: 2022-12-11
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT03229382: Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse
Official title: Evaluation of Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse After First Line Immunochemotherapy With Autologous Stem Cell (ML29157).
Acronym: OPERA-PLRG10
Sponsor: Polish Lymphoma Research Group (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Very slow recruitment due to lack of relapse in the observed group of patients
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-05-14
Primary completion date: 2020-01-31
Completion date: 2020-01-31
Clinical trial NCT02514031: ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer
Official title: A Phase I/Ib, Single-Arm, Open-Label, Multi-Center Trial Using ARQ-761 (Beta-Lapachone) Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Metastatic, Unresectable, Or Recurrent Pancreatic Cancer
Sponsor: University of Texas Southwestern Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study placed on temporarily hold to enrollment due to quality testing necessary for the study drug.
Enrollment: 17.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-03-24
Primary completion date: 2018-05-22
Completion date: 2022-05-31
Clinical trial NCT05113901: Medrol Dosepak Taper for Delayed Post-op Recovery After TKA
Official title: Methylprednisolone Taper to Treat Delayed Post-Operative Recovery After Total Knee Arthroplasty: a Double-Blind Randomized Controlled Trial
Sponsor: Rush University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Extremely low participation, decided to focus on similar study instead
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-03-03
Primary completion date: 2022-07-01
Completion date: 2022-07-25
Baseline population: The study was terminated early, only 4 subjects were consented, none were randomized to the placebo by the time the study ended.
Plan to share individual participant data: NO
Clinical trial NCT05062577: A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder
Sponsor: Astellas Pharma Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Due to corporate strategic considerations
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-08
Primary completion date: 2023-02-28
Completion date: 2023-02-28
Plan to share individual participant data: NO
IPD sharing description: Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under Sponsor Specific Details for Astellas.
Clinical trial NCT01784861: VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
Official title: A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, With Everolimus for Patients With Pancreatic Neuroendocrine Tumors
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Pharmaceutical company decision
Enrollment: 23.0 (ACTUAL)
Number of arms: 6.0
Start date: 2013-05-03
Primary completion date: 2020-08-19
Completion date: 2020-08-19
Plan to share individual participant data: NO